Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
Expert Rev Neurother
; 14(11): 1243-50, 2014 Nov.
Article
em En
| MEDLINE
| ID: mdl-25331416
ABSTRACT
Refractory spasticity, central neuropathic pain and bladder dysfunction are common clinical problems in patients with multiple sclerosis (MS). None of the currently available oral medications has proven to be reliably effective and can be limited by toxicity. Cannabinoids have shown therapeutic effects on those MS-associated symptoms. Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) Sativex (nabiximols) is an oromucosal spray formulation that contains THC and CBD in an approximate 11 ratio and is described as an endocannabinoid system modulator. The efï¬cacy of THC/CBD on MS-associated spasticity, pain and bladder dysfunction has been studied in clinical trials as well as in clinical practice studies. Adverse effects are usually mild or moderate and the low rate of drug discontinuation provides good evidence of long-term tolerability. This article focuses on the pharmacological properties, clinical efï¬cacy and tolerability of THC/CBD in MS patients.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Extratos Vegetais
/
Esclerose Múltipla
/
Espasticidade Muscular
/
Neuralgia
Limite:
Humans
Idioma:
En
Revista:
Expert Rev Neurother
Assunto da revista:
NEUROLOGIA
/
TERAPEUTICA
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Espanha